Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Additional Exempt Distribution
2023-09-26 (Alberta)
Promissory Note: $337,725.00 (CAN)
With 450,000 warrants @ $1.01, Expire 2023-09-26.
Koo